sofosbuvir + ledipasvir or sofosbuvir + daclatasvir

Sofosbuvir + ledipasvir and sofosbuvir + daclatasvir are two potent oral, small-molecule, direct-acting antiviral (DAA) combination regimens used for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir is a pangenotypic nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. Ledipasvir and daclatasvir are both inhibitors of the HCV NS5A protein, a multifunctional protein involved in viral RNA replication and the assembly of HCV virions. The sofosbuvir/ledipasvir combination is marketed as a fixed-dose single tablet (Harvoni, developed by Gilead Sciences), while sofosbuvir/daclatasvir involves the co-administration of two separate drugs (Sovaldi and Daklinza, developed by Gilead and Bristol Myers Squibb, respectively). These regimens have revolutionized HCV treatment, offering high cure rates (SVR12 >90%) with a favorable safety profile and a typical treatment duration of 12 weeks. In Egypt, these DAAs have been central to the national campaign to eliminate HCV, particularly targeting genotype 4, which is predominant in the region.

Brand names

HarvoniDaklinzaSovaldi

Other names

sofosbuvir + ledipasvirsofosbuvir + daclatasvirsofosbuvir/ledipasvirsofosbuvir/daclatasvir